Association of response endpoints with survival outcomes in multiple myeloma.
about
Treatment of relapsed and refractory multiple myelomaNew criteria for response assessment: role of minimal residual disease in multiple myelomaThe Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveBendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.Curing myeloma at last: defining criteria and providing the evidence.Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trialsT-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of ImmunotherapyMultiple myeloma: patient outcomes in real-world practice.Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease responseTretatment approach of nontransplant patients with multiple myelomaModern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model.Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis.Standardisation of minimal residual disease in multiple myeloma.Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy.Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple MyelomaNext Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.Outcome and survival of myeloma patients diagnosed 2008-2015. Real world data on 4904 patients from the Swedish Myeloma Registry (SMR).Model-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development.Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.Tissue Engineering Platforms to Replicate the Tumor Microenvironment of Multiple Myeloma.Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPRelationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma.Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myelomaRole of the Advanced Practice Provider in Clinical Trials: Contributions to the Management of Patients Receiving Inotuzumab OzogamicinInterpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
P2860
Q26749180-C59684D9-86AE-41DF-A7A3-407BEBD5406CQ27027512-6A4C594B-59CD-4C5E-BA2A-BBF4A8FB9D9EQ28069789-F78CCEED-89AA-41A5-A3E8-3AF2ABCAADD3Q33437691-922F70D5-1D0D-4F64-A244-28FCA8F4CE92Q33602593-0BCAC6E2-1A6D-4D38-B922-64B17F8A7768Q34508313-0CE9E976-5328-4B7E-AE4B-D63B051CC6A1Q35539175-F006CF2E-BA73-4F6F-A4CC-FE04EDF4AB89Q35760754-A650D78F-55D7-4D4B-AE67-EFA5FA89AC32Q36436758-1F0A9C4D-2955-4DCC-8A90-A04E5B455436Q37394605-A2206701-35AD-48DD-A3B4-9E08007A6062Q37593761-B7A9F043-0E23-4D4E-89BF-5E32949B4172Q38311072-BCA99E2A-96F0-47CD-BA42-20E861D79BA9Q38756800-38199B95-23D5-472B-8535-0334464EA841Q38896793-D0CF77E2-769A-43D6-A7C6-9314C3FA7B27Q38947433-F59137E7-A853-4BA6-9966-AB2075CFD608Q38971754-04CBC27E-6077-41AD-8E32-EE85C1262D4CQ39410899-E00F79D3-38FF-4230-B782-35CAB9B04069Q40469944-95DCD12B-DEB9-4610-AC80-8C0C69F035CAQ40470311-04EF9C81-D178-461C-97D0-44079328B83BQ41370609-B192B227-A83B-4BD0-8CB5-62C20842ABD0Q42050819-62F268B6-A608-4481-9381-DE271C41B212Q42940568-467B17E1-41C1-466A-A9E7-7BD024D5E38BQ43921722-5BC6BA7A-796A-4EFF-A6CD-ACC103E7A56DQ46427111-32BF239F-3794-4629-967E-CE7FC8039B93Q47149240-7BA66758-441B-4C38-BF86-011632095EA7Q47198067-EF2E2702-6EF7-4E05-ABFE-7AFDC049AD38Q47423761-F2C6B288-64BD-4796-99DC-61ED8303BC99Q49931866-E1AD5A1C-E59F-4D3D-A96C-FA48B1022532Q50089402-390B1944-CBF8-403B-AF55-6939F363593EQ51035100-EAA7E240-F625-4228-9059-0F466AA35F15Q51110620-DBD79CE5-3606-4319-B4A6-D8053E210D5AQ52609413-8BC1E8DD-FB3B-4E38-B08B-0E839670D073Q53786308-7695A738-A6DD-4A4D-A27D-391E0D10F4D9Q55208548-6CBE7348-DDC5-4B94-B404-472D0551AAF8Q56967485-8FE1FDF4-089F-490A-BF6C-266C700D88A9Q57498744-8881B16F-2C10-4108-9D0C-A171C42146A6Q58560605-E5669971-B96B-4665-9E16-8CE7B8F21ED5
P2860
Association of response endpoints with survival outcomes in multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Association of response endpoints with survival outcomes in multiple myeloma.
@en
type
label
Association of response endpoints with survival outcomes in multiple myeloma.
@en
prefLabel
Association of response endpoints with survival outcomes in multiple myeloma.
@en
P2860
P356
P1433
P1476
Association of response endpoints with survival outcomes in multiple myeloma.
@en
P2093
K C Anderson
P2860
P2888
P304
P356
10.1038/LEU.2013.220
P5008
P577
2013-07-19T00:00:00Z
2014-02-01T00:00:00Z
P5875
P6179
1017507834